Behavioral effects of novelty and VTA inactivation. Related to Figure 1.
(A) In novel sessions, Unch. visit duration decreased from Epoch 1 to Epoch 2, while CNO additionally led to longer visit duration in experimental rats. Mean ± standard error, Exp Saline, Epoch 1: 7.181±0.33, Epoch 2: 4.892±0.2, two sample t-test: t(348)=5.836, p<10-5; Exp CNO, Epoch 1: 10.542±0.65, Epoch 2: 6.789±0.41, two sample t-test: t(297)=5.012, p<10-5. Con Saline, Epoch 1: 7.594±0.28, Epoch 2: 4.8±0.14, two sample t-test: t(401)=9.054, p<10-10; Con CNO, Epoch 1: 7.267±0.26, Epoch 2: 4.834±0.12, two sample t-test: t(426)=8.471, p<10-10. Three-way ANOVA with epoch, drug, and animal group: epoch (F[1,1472]=171.66, p<10-10), drug (F[1,1472]=33.3, p<10-5), group (F[1,1472]=32.57, p<10-5), drug X group (F[1,1472]=41.66, p<10-5), epoch X drug X group (F[1,1472]=4.5, p=0.034). (B) In novel sessions, Incr. visit duration increased from Epoch 1 to Epoch 2, while CNO additionally led to longer visit duration in experimental rats. Mean ± standard error, Exp Saline, Epoch 1: 7.179±0.39, Epoch 2: 9.968±0.3, two sample t-test: t(343)=-5.668, p<10-6; Exp CNO, Epoch 1: 10.16±0.74, Epoch 2: 13.721±0.48, two sample t-test: t(293)=-4.164, p=0.00004. Con Saline, Epoch 1: 7.478±0.29, Epoch 2: 10.907±0.24, two sample t-test: t(395)=-9.086, p<10-10; Con CNO, Epoch 1: 6.65±0.21, Epoch 2: 10.506±0.15, two sample t-test: t(420)=-15.18, p<10-10. Three-way ANOVA with epoch, drug, and animal group: epoch (F[1,1451]=192.37, p<10-10), drug (F[1,1451]=31.38, p<10-5), group (F[1,1451]=31.16, p<10-5), drug X group (F[1,1451]=65.62, p<10-10). (C) In familiar sessions, Unch. visit duration decreased from Epoch 1 to Epoch 2, with only a modest effect of CNO compared to novel sessions. Mean ± standard error, Exp Saline, Epoch 1: 6.011±0.2, Epoch 2: 4.7±0.18, two sample t-test: t(1180)=4.806, p<10-4; Exp CNO, Epoch 1: 6.037±0.18, Epoch 2: 5.371±0.17, two sample t-test: t(1053)=2.712, p=0.0068. Con Saline, Epoch 1: 5.969±0.17, Epoch 2: 4.465±0.13, two sample t-test: t(746)=7.057, p<10-10; Con CNO, Epoch 1: 6.035±0.13, Epoch 2: 4.174±0.07, two sample t-test: t(858)=13.165, p<10-10. Three-way ANOVA with epoch, drug, and animal group: epoch (F[1,3837]=120.87, p<10-10), group (F[1,3837]=9.22, p=0.0024), epoch X group (F[1,3837]=8.15, p=0.0043), epoch X drug X group (F[1,3837]=4.26, p=0.0391). (D) In familiar sessions, Incr. visit duration increased from Epoch 1 to Epoch 2. Mean ± standard error, Exp Saline, Epoch 1: 6.058±0.19, Epoch 2: 10.463±0.24, two sample t-test: t(1169)=-14.293, p<10-10; Exp CNO, Epoch 1: 5.77±0.18, Epoch 2: 11.07±0.29, two sample t-test: t(1045)=-15.654, p<10-10. Con Saline, Epoch 1: 6.519±0.2, Epoch 2: 11.12±0.23, two sample t-test: t(741)=-14.979, p<10-10; Con CNO, Epoch 1: 6.018±0.15, Epoch 2: 10.206±0.15, two sample t-test: t(852)=-19.849, p<10-10. Three-way ANOVA with epoch, drug, and animal group: epoch (F[1,3807]=885.39, p<10-10), drug X group (F[1,3807]=7.78, p=0.0053), epoch X drug X group (F[1,3807]=4.44, p=0.0352). (E) Unch. visit duration increased from Epoch 2 to Epoch 3. Mean ± standard error, Exp Saline, Epoch 2: 4.743±0.15, Epoch 3: 7.274±0.23, two sample t-test: t(1354)=-9.542, p<10-10; Exp CNO, Epoch 2: 5.705±0.16, Epoch 3: 6.898±0.27, two sample t-test: t(1096)=-4.031, p=10-5. Con Saline, Epoch 2: 4.58±0.1, Epoch 3: 6.05±0.18, two sample t-test: t(939)=-7.838, p<10-10; Con CNO, Epoch 2: 4.391±0.06, Epoch 3: 6.049±0.13, two sample t-test: t(1033)=-12.818, p<10-10. Three-way ANOVA with epoch, drug, and animal group: epoch (F[1,4422]=196.47, p<10-10), group (F[1,4422]=52.77, p<10-5), epoch X drug (F[1,4422]=5.53, p=0.0187), epoch X drug X group (F[1,4422]=9.74, p=0.0018). (F) Incr. visit duration decreased from Epoch 2 to Epoch 3. Mean ± standard error, Exp Saline, Epoch 2: 10.351±0.2, Epoch 3: 7.878±0.31, two sample t-test: t(1369)=6.993, p<10-10; Exp CNO, Epoch 2: 11.691±0.25, Epoch 3: 7.718±0.35, two sample t-test: t(1116)=9.437, p<10-10. Con Saline, Epoch 2: 11.047±0.17, Epoch 3: 6.578±0.18, two sample t-test: t(958)=17.166, p<10-10; Con CNO, Epoch 2: 10.304±0.11, Epoch 3: 6.296±0.17, two sample t-test: t(1057)=20.98, p<10-10. Three-way ANOVA with epoch, drug, and animal group: epoch (F[1,4500]=491.46, p<10-10), group (F[1,4500]=25.7, p<10-5), epoch X group (F[1,4500]=9.11, p=0.0026), drug X group (F[1,4500]=10.72, p=0.0011), epoch X drug X group (F[1,4500]=8.49, p=0.0036).